New strategies and perspectives on managing IgA nephropathy
Open accessThe DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Abstract
IgA nephropathy is an inflammatory renal disease characterised by the deposition of IgA in the glomerular mesangium and is the most commonly reported primary glomerulonephritis worldwide. Thirty to forty percent of patients with the disease develop progressive renal function decline, requiring renal replacement therapy within two decades of diagnosis. Despite this, accurate individual risk stratification at diagnosis and predicting treatment response remains a challenge. Furthermore, there are currently no disease specific treatments currently licensed to treat the condition due to long standing challenges in the nature and prevalence of the disease. Despite this, there have been exciting recent advances in the field that may represent paradigm shifts in the way IgA nephropathy is managed in the near future. In this review, we explore the evidence base informing current approaches to management and explore new strategies and future directions in the diagnosis and management of IgA nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are no commercially available disease-speci fi c therapies for IgA nephropathy, 4 in part because no largescale, randomized clinical trials have demonstrated a reduction in mortality or in major adverse kidney or cardiovascular events with any therapeutic intervention.”
From A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy (2021) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although IgA nephropathy is an immune-mediated disease, with mucosalderived IgA forming circulating immune complexes that deposit in the mesangium, 1 the role of immunosuppressive therapy remains controversial and is usually reserved for patients who do not respond to supportive measures.”
From A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy (2021) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007) · Nature · doi:10.1038/nature06244 · Cited by 6,091
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Body Mass Index and Risk for End-Stage Renal Disease
Hsu, C.-Y., McCulloch, C. E., Iribarren, C., Darbinian, J., & Go, A. S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-1-200601030-00006 · Cited by 1,390
Wyatt, R. J., & Julian, B. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1206793 · Cited by 1,222
A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts, I. S. D., Cook, H. T., Troyanov, S., Alpers, C. E., Amore, A., Barratt, J., Berthoux, F., Bonsib, S., Bruijn, J. A., et al. (2009) · Kidney International · doi:10.1038/ki.2009.168 · Cited by 1,038
Self-citationROLE OF C5A IN INFLAMMATORY RESPONSES
Guo, R.-F., & Ward, P. A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115835 · Cited by 1,021
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.9 · Cited by 966
The Pathophysiology of IgA Nephropathy
Suzuki, H., Kiryluk, K., Novak, J., Moldoveanu, Z., Herr, A. B., Renfrow, M. B., Wyatt, R. J., Scolari, F., Mestecky, J., Gharavi, A. G., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011050464 · Cited by 910
KDIGO Clinical Practice Guideline for Glomerulonephritis
Eckardt, K., & Kasiske, B. L. (2012) · Cited by 894
[Intercapillary deposits of IgA-IgG].
Berger, J., & Hinglais, N. (1968) · PubMed · Cited by 800
Infectious diseases associated with complement deficiencies
Figueroa, J. E., & Densen, P. (1991) · Clinical Microbiology Reviews · doi:10.1128/cmr.4.3.359 · Cited by 729
Intensive supportive care plus immunosuppression in IgA nephropathy
Rauen, T., Eitner, F., Fitzner, C., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415463 · Cited by 726
Remission of Proteinuria Improves Prognosis in IgA Nephropathy
Reich, H. N., Troyanov, S. A. A., Scholey, J. W., & Cattran, D. C. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050526 · Cited by 639
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
Jayne, D. R. W., Bruchfeld, A. N., Harper, L., Schaier, M., Venning, M. C., Hamilton, P., Burst, V., Grundmann, F., Jadoul, M., Szombati, I., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016111179 · Cited by 607
Body mass index and the risk of development of end-stage renal disease in a screened cohort
Iseki, K., Ikemiya, Y., Kinjo, K., Inoue, T., Iseki, C., & Takishita, S. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00582.x · Cited by 603
Corticosteroids in IgA nephropathy: a randomised controlled trial
Pozzi, C., Bolasco, P., Fogazzi, G., Andrulli, S., Altieri, P., Ponticelli, C., & Locatelli, F. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03563-6 · Cited by 532
Coppo, R., on behalf of the VALIGA study of the ERA-EDTA Immunonephrology Working Group, Troyanov, S., Bellur, S., Cattran, D., Cook, H. T., Feehally, J., Roberts, I. S. D., Morando, L., Camilla, R., et al. (2014) · Kidney International · doi:10.1038/ki.2014.63 · Cited by 498
Self-citationRoos, A., Rastaldi, M. P., Calvaresi, N., Oortwijn, B. D., Schlagwein, N., van Gijlswijk-Janssen, D. J., Stahl, G. L., Matsushita, M., Fujita, T., van Kooten, C., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005090923 · Cited by 450
Fellström, B. C., Barratt, J., Cook, H., Coppo, R., Feehally, J., de Fijter, J. W., Floege, J., Hetzel, G., Jardine, A. G., Locatelli, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30550-0 · Cited by 414 · cited 1×
“The study demonstrated a significant reduction in proteinuria after 9 months treatment with TRFbudesonide, and although more adverse events were noted with treatment, this did not reach statistical significance [81, 83].”
Self-citationLe, W., Liang, S., Hu, Y., Deng, K., Bao, H., Zeng, C., & Liu, Z. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr527 · Cited by 411
A Controlled Trial of Fish Oil in IgA Nephropathy
Donadio, J. V., Bergstralh, E. J., Offord, K. P., Spencer, D. C., & Holley, K. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311804 · Cited by 408
Kiryluk, K., Li, Y., Sanna-Cherchi, S., Rohanizadegan, M., Suzuki, H., Eitner, F., Snyder, H. J., Choi, M., Hou, P., Scolari, F., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002765 · Cited by 383
Low protein diets for chronic kidney disease in non diabetic adults
Fouque, D., & Laville, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001892.pub3 · Cited by 356
Treatment of IgA Nephropathy with ACE Inhibitors: A Randomized and Controlled Trial
Praga, M., Gutiérrez, E., González, E., Morales, E., & Hernández, E. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000068460.37369.dc · Cited by 345
Protein degradation and the generation of MHC class I-presented peptides
Rock, K. L., York, I. A., Saric, T., & Goldberg, A. L. (2002) · Advances in Immunology · doi:10.1016/s0065-2776(02)80012-8 · Cited by 339
Current Understanding of the Role of Complement in IgA Nephropathy
Maillard, N., Wyatt, R. J., Julian, B. A., Kiryluk, K., Gharavi, A., Fremeaux-Bacchi, V., & Novak, J. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014101000 · Cited by 338
Smoking as a risk factor for end-stage renal failure in men with primary renal disease
Orth, S. R., Stöckmann, A., Conradt, C., Ritz, E., Ferro, M., Kreusser, W., Piccoli, G., Rambausek, M., Roccatello, D., Schäfer, K., et al. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00067.x · Cited by 314
Bonnet, F., Deprele, C., Sassolas, A., Moulin, P., alamartine, E., Berthezène, F., & Berthoux, F. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80120-7 · Cited by 311
Manno, C., Torres, D. D., Rossini, M., Pesce, F., & Schena, F. P. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp356 · Cited by 311
Isenberg, D., Gordon, C., Licu, D., Copt, S., Rossi, C. P., Wofsy, D., Babini, A., Lazaro, M., Lucero, E., Merono, C., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205067 · Cited by 306
Lafayette, R. A., Canetta, P. A., Rovin, B. H., Appel, G. B., Novak, J., Nath, K. A., Sethi, S., Tumlin, J. A., Mehta, K., Hogan, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060640 · Cited by 300
Mice overexpressing BAFF develop a commensal flora–dependent, IgA-associated nephropathy
McCarthy, D. D., Kujawa, J., Wilson, C., Papandile, A., Poreci, U., Porfilio, E. A., Ward, L., Lawson, M. A. E., Macpherson, A. J., McCoy, K. D., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45563 · Cited by 286
Epidemiology, impact and preventive care of chronic kidney disease in Taiwan
HWANG, S., TSAI, J., & CHEN, H. (2010) · Nephrology · doi:10.1111/j.1440-1797.2010.01304.x · Cited by 283
Roberts, I. S. D. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.92 · Cited by 263
Coppo (2007) · doi:10.1681/asn.2006040347 · Cited by 256
Microbiota and Metabolome Associated with Immunoglobulin A Nephropathy (IgAN)
De Angelis, M., Montemurno, E., Piccolo, M., Vannini, L., Lauriero, G., Maranzano, V., Gozzi, G., Serrazanetti, D., Dalfino, G., Gobbetti, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099006 · Cited by 239
Lv, J., Zhang, H., Chen, Y., Li, G., Jiang, L., Singh, A. K., & Wang, H. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.07.029 · Cited by 238
Li, P. K.-T., Leung, C. B., Chow, K. M., Cheng, Y. L., Fung, S. K.-S., Mak, S. K., Tang, A. W.-C., Wong, T. Y.-H., Yung, C. Y., Yung, J. C.-U., et al. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.01.017 · Cited by 223
Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases
Samy, E., Wax, S., Huard, B., Hess, H., & Schneider, P. (2017) · International Reviews of Immunology · doi:10.1080/08830185.2016.1276903 · Cited by 220
The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy
Xie, Y., Nishi, S., Ueno, M., Imai, N., Sakatsume, M., Narita, I., Suzuki, Y., Akazawa, K., Shimada, H., Arakawa, M., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00935.x · Cited by 212
Effects of weight loss on renal function in obese CKD patients: a systematic review
Bolignano, D., & Zoccali, C. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft302 · Cited by 211
Leonard, J. P., Kolibaba, K. S., Reeves, J. A., Tulpule, A., Flinn, I. W., Kolevska, T., Robles, R., Flowers, C. R., Collins, R., DiBella, N. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.2784 · Cited by 186
Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection
Shin, E.-C., Seifert, U., Kato, T., Rice, C. M., Feinstone, S. M., Kloetzel, P.-M., & Rehermann, B. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29832 · Cited by 185
Endo, M. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.8.1984 · Cited by 182
Kawamura, T., Yoshimura, M., Miyazaki, Y., Okamoto, H., Kimura, K., Hirano, K., Matsushima, M., Utsunomiya, Y., Ogura, M., Yokoo, T., et al. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu020 · Cited by 180
Barbour, S. J., Cattran, D. C., Kim, S. J., Levin, A., Wald, R., Hladunewich, M. A., & Reich, H. N. (2013) · Kidney International · doi:10.1038/ki.2013.210 · Cited by 164
Komatsu, H., Fujimoto, S., Hara, S., Sato, Y., Yamada, K., & Kitamura, K. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00310108 · Cited by 160
Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy
Zhai, Y.-L., Zhu, L., Shi, S.-F., Liu, L.-J., Lv, J.-C., & Zhang, H. (2016) · Medicine · doi:10.1097/md.0000000000003099 · Cited by 132
Melanocortin 1 Receptor Agonists Reduce Proteinuria
Lindskog, A., Ebefors, K., Johansson, M., Stefánsson, B. V., Granqvist, A., Árnadóttir, M., Berg, A., Nystrom, J. C., & Haraldsson, B. S. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009101025 · Cited by 126
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
Sanchorawala, V., Palladini, G. O., Kukreti, V., Zonder, J. A., Cohen, A. D., Seldin, D. C., Dispenzieri, A. A., Jaccard, A., Schönland, S. O., Berg, D. T., et al. (2017) · Blood · doi:10.1182/blood-2017-03-771220 · Cited by 124
Pettersson, E. E., Rekola, S., Berglund, L., Sundqvist, K., Angelin, B., Diczfalusy, U., Björkhem, I., & Bergström, J. (1994) · PubMed · Cited by 120
Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis
Suzuki, H. (2018) · Clinical and Experimental Nephrology · doi:10.1007/s10157-018-1582-2 · Cited by 119
Chapter 10: Immunoglobulin A nephropathy
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.23 · Cited by 119
Low protein diets for chronic kidney disease in non diabetic adults
Fouque, D., Laville, M., & Boissel, J.-P. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001892.pub2 · Cited by 119
Tonsillectomy does not prevent a progressive course in IgA nephropathy.
Rasche, F. M., Schwarz, A., & Keller, F. (1999) · PubMed · Cited by 117
IgA1 molecules produced by tonsillar lymphocytes are under-O-glycosylated in IgA nephropathy
Horie, A., Hiki, Y., Odani, H., Yasuda, Y., Takahashi, M., Kato, M., Iwase, H., Kobayashi, Y., Nakashima, I., & Maeda, K. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00743-1 · Cited by 106
Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy
Rauen, T., Fitzner, C., Eitner, F., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017060713 · Cited by 104
Cigarette Smoking and Progression of IgA Nephropathy
Yamamoto, R., Nagasawa, Y., Shoji, T., Iwatani, H., Hamano, T., Kawada, N., Inoue, K., Uehata, T., Kaneko, T., Okada, N., et al. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.02.351 · Cited by 103
Nakata, J., Suzuki, Y., Suzuki, H., Sato, D., Kano, T., Yanagawa, H., Matsuzaki, K., Horikoshi, S., Novák, J., & Tomino, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089707 · Cited by 101
Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy
Feehally, J., Coppo, R., Troyanov, S., Bellur, S. S., Cattran, D., Cook, T., Roberts, I. S. D., Verhave, J. C., Camilla, R., Vergano, L., et al. (2016) · Nephron · doi:10.1159/000441852 · Cited by 92
McCarthy, D. D., Chiu, S., Gao, Y., deLuca, L. S., & Gommerman, J. L. (2006) · Cellular Immunology · doi:10.1016/j.cellimm.2006.08.002 · Cited by 87
Overweight/obesity revisited as a predictive risk factor in primary IgA nephropathy
Berthoux, F. C., Mariat, C., & Maillard, N. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft286 · Cited by 84
Ferraro, P. M., Ferraccioli, G., Gambaro, G., Fulignati, P., & Costanzi, S. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn454 · Cited by 83
ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials
Cheng, J., Zhang, W., Zhang, X. H., He, Q., Tao, X. J., & Jh, C. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02038.x · Cited by 81
Kim, M. J., McDaid, J., McAdoo, S. P., Barratt, J., Molyneux, K., Masuda, E. S., Pusey, C. D., & Tam, F. W. K. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102603 · Cited by 80
Self-citationTLR9 and BAFF: Their expression in patients with IgA nephropathy
LI, W., PENG, X., LIU, Y., LIU, H., LIU, F., HE, L., LIU, Y., ZHANG, F., GUO, C., CHEN, G., et al. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2359 · Cited by 80
Coppo, R., Camilla, R., Alfarano, A., Balegno, S., Mancuso, D., Peruzzi, L., Amore, A., Canton, A. D., Sepe, V., & Tovo, P. (2008) · Kidney International · doi:10.1038/ki.2008.579 · Cited by 78
Role of complement in IgA nephropathy
Daha, M. R., & van Kooten, C. (2015) · Journal of Nephrology · doi:10.1007/s40620-015-0245-6 · Cited by 74
Non-immunosuppressive treatment for IgA nephropathy
Reid, S., Cawthon, P. M., Craig, J. C., Samuels, J. A., Molony, D. A., & Strippoli, G. F. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003962.pub2 · Cited by 72
C3a, C5a Renal Expression and Their Receptors are Correlated to Severity of IgA Nephropathy
Liu, L., Zhang, Y., Duan, X., Peng, Q., Liu, Q., Zhou, Y., Quan, S., & Xing, G. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-013-9970-6 · Cited by 71
IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy
Lechner, S. M., Abbad, L., Boedec, E., Papista, C., Stang, M.-B. L., Moal, C., Maillard, J., Jamin, A., Bex-Coudrat, J., Wang, Y., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015080856 · Cited by 69
An Overview of Regular Dialysis Treatment in Japan (as of 31 December 2004)
Nakai, S., Wada, A., Kitaoka, T., Shinzato, T., Nagura, Y., Kikuchi, K., Masakane, I., Shinoda, T., Yamazaki, C., Sakai, R., et al. (2006) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2006.00440.x · Cited by 65
Novák, J., Moldoveanu, Z., Julian, B. A., Raška, M., Wyatt, R. J., Suzuki, Y., Tomino, Y., Gharavi, A. G., Mestecky, J. F., & Suzuki, H. (2011) · Advances in oto-rhino-laryngology · doi:10.1159/000324607 · Cited by 62
Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series
Madan, A., Mijovic-Das, S., Stankovic, A. R., Teehan, G. S., Milward, A. S., & Khastgir, A. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0241-7 · Cited by 61
Leveraging Melanocortin Pathways to Treat Glomerular Diseases
Gong, R. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2013.09.004 · Cited by 59
Lamm, M. E., Emancipator, S. N., Robinson, J., Yamashita, M., Fujioka, H., Qiu, J., & Plaut, A. G. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070131 · Cited by 57
Alexopoulos, E., Stangou, M., Pantzaki, A., Kirmizis, D., & Memmos, D. (2004) · Renal Failure · doi:10.1081/jdi-200026763 · Cited by 52
Itoh, A., Iwase, H., Takatani, T., Nakamura, I., Hayashi, M., Oba, K., Hiki, Y., Kobayashi, Y., & Okamoto, M. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg108 · Cited by 52
McAdoo, S. P., Bhangal, G., Page, T. H., Cook, H. T., Pusey, C. D., & Tam, F. W. K. (2015) · Kidney International · doi:10.1038/ki.2015.29 · Cited by 51
Konishi, Y., Okada, N., Okamura, M., Morikawa, T., Okumura, M., Yoshioka, K., & Imanishi, M. (2001) · Hypertension · doi:10.1161/01.hyp.38.1.81 · Cited by 49
Immunoglobulin A nephropathy: a pathophysiology view
Fabiano, R. C. G., Pinheiro, S. V. B., & Silva, A. C. S. E. (2016) · Inflammation Research · doi:10.1007/s00011-016-0962-x · Cited by 49
Ouyang, Y., Xie, J., Yang, M., Zhang, X., Ren, H., Wang, W., & Chen, N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162044 · Cited by 48
Maeng, Y., Kim, M., Park, J.-B., Cho, C., Oh, H. K., Sung, W. J., & Park, K. (2013) · Europe PMC (PubMed Central) · Cited by 47
Taylor, P. C., Genovese, M. C., Greenwood, M., Ho, M., Nasonov, E. L., Oemar, B. S., Stoilov, R. M., Vencovský, J., & Weinblatt, M. E. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205361 · Cited by 47
Epidemiology of Glomerular Disease in Southern Arizona
Murugapandian, S., Mansour, I. S. M., Hudeeb, M., Hamed, K., Hammode, E., Bijin, B., Daheshpour, S., Thajudeen, B., & Kadambi, P. V. (2016) · Medicine · doi:10.1097/md.0000000000003633 · Cited by 46
Cheng, J.-P., Zhang, X.-Z., Tian, J., Li, Q., & Chen, J.-H. (2012) · International journal of clinical practice · doi:10.1111/j.1742-1241.2012.02970.x · Cited by 40
Tanaka, M., Yamada, S., Iwasaki, Y., Sugishita, T., Yonemoto, S., Tsukamoto, T., Fukui, S., Takasu, K., & Muso, E. (2009) · Nephron Clinical Practice · doi:10.1159/000213084 · Cited by 40
Long‐term outcomes for primary glomerulonephritis: N ew Z ealand G lomerulonephritis S tudy
Chembo, C. L., Marshall, M. R., Williams, L. C., Walker, R. J., Lynn, K. L., Irvine, J. H., & Pilmore, H. (2015) · Nephrology · doi:10.1111/nep.12538 · Cited by 40
Lenert, A., Niewold, T. B., & Lenert, P. S. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s114552 · Cited by 39
Ma, T. K.-W., McAdoo, S. P., & Tam, F. W. K. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw336 · Cited by 30
MicroRNAs: a new avenue to understand, investigate and treat immunoglobulin A nephropathy?
Selvaskandan, H., Pawluczyk, I. Z. A., & Barratt, J. (2017) · Clinical Kidney Journal · doi:10.1093/ckj/sfx096 · Cited by 30
Self-citationImpact of Body Mass Index on Progression of IgA Nephropathy Among Japanese Patients
Shimamoto, M., Ohsawa, I., Suzuki, H., Hisada, A., Nagamachi, S., Honda, D., Inoshita, H., Shimizu, Y., Horikoshi, S., & Tomino, Y. (2014) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.21778 · Cited by 29
Kittiskulnam, P., Kanjanabuch, T., Tangmanjitjaroen, K., Chancharoenthana, W., Praditpornsilpa, K., & Eiam‐Ong, S. (2014) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2014.01.016 · Cited by 28
TESTING Corticosteroids in IgA Nephropathy: A Continuing Challenge
Tam, F. W. K., & Pusey, C. D. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10560917 · Cited by 22
Con: STOP immunosuppression in IgA nephropathy
Rauen, T., Eitner, F., Fitzner, C., & Floege, J. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw286 · Cited by 21
Pro: STOP immunosuppression in IgA nephropathy?
Pozzi, C. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw285 · Cited by 20
Tonsillectomy and IgA nephritis
Ponticelli, C. E. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs093 · Cited by 18
Clinicopathological Influence of Obesity in IgA Nephropathy: Comparative Study of 74 Patients
Tanaka, M., Tsujii, T., Komiya, T., Iwasaki, Y., Sugishita, T., Yonemoto, S., Tsukamoto, T., Fukui, S., Takasu, A., & Muso, E. (2007) · KARGER eBooks · doi:10.1159/000102309 · Cited by 14
An update on the treatment of IgA nephropathy
Barbour, S. J., & Feehally, J. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000336 · Cited by 14
Smoking-Related Renal Histologic Injury in IgA Nephropathy Patients
Cha, Y. J., Lim, B. J., Kim, B. S., Kim, Y., Yoo, T., Han, S. H., Kang, S., Choi, K. H., & Jeong, H. J. (2015) · Yonsei Medical Journal · doi:10.3349/ymj.2016.57.1.209 · Cited by 13
Immunosuppression in IgA Nephropathy: Guideline Medicine Versus Personalized Medicine
Feehally, J. (2017) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2017.05.019 · Cited by 13
IgA nephropathy: toward more specific diagnosis (and rescue of snails)
Floege, J. (2018) · Kidney International · doi:10.1016/j.kint.2017.10.028 · Cited by 12
Mucosal corticosteroid therapy of IgA nephropathy
Floege, J. (2017) · Kidney International · doi:10.1016/j.kint.2017.05.021 · Cited by 11
Bahleda, R., Deley, M. L., Bernard, A., Chaturvedi, S., Hanley, M. J., Poterie, A., Gazzah, A., Varga, A., Touat, M., Deutsch, É., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0531-3 · Cited by 11
Koulouridis, E., & Koulouridis, I. (2011) · Europe PMC (PubMed Central) · Cited by 8
Matsumoto, K., Ikeda, Y., Yamaguchi, S., Sanematsu, M., Fukuda, M., Takashima, T., Kishi, T., Miyazono, M., Uchiumi, S., Yoshizaki, M., et al. (2017) · Nephrology · doi:10.1111/nep.13108 · Cited by 8
Suzuki, T., Miyazaki, Y., Shimizu, A., Ito, Y., Okonogi, H., Ogura, M., Utsunomiya, Y., Kawamura, T., & Hosoya, T. (2009) · Clinical Nephrology · doi:10.5414/cnp72274 · Cited by 7
Bahleda, R., Deley, M. L., Bernard, A., Chaturvedi, S., Gazzah, A., Varga, A., Keung, C., Deutsch, É., Massard, C., de Velde, H. J. V., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2623 · Cited by 3
IgA nephropathy: driving innovation with a rare renal disease registry
Selvaskandan, H., Dillon, M., & Barratt, J. (2017) · Journal of Kidney Care · doi:10.12968/jokc.2017.2.4.205 · Cited by 3
Self-citation
Research works printed but not linked: 1
- Edsbäcker S Wollmer P Nilsson A Nillson M Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsules Gastroenterology 1993 104 A695
Cited by
Wheeler, D. C., Toto, R. D., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Pecoits-Filho, R., Correa-Rotter, R., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.033 · Cited by 420
“Other potential therapeutic approaches, some of which are being assessed in ongoing trials, include inhibition of endothelin-1 (NCT04663204 and NCT04573478), inhibition of complement activation, and proteasome inhibitors.(4)”
BackgroundLv, J., Wong, M. G., Hladunewich, M. A., Jha, V., Hooi, L. S., Monaghan, H., Zhao, M., Barbour, S., Jardine, M. J., Reich, H. N., et al. (2022) · JAMA · doi:10.1001/jama.2022.5368 · Cited by 354
Yang, F., Ni, J., Wang, Y.-S., Zhao, Y., Jiang, L.-Q., Chen, C., Zhang, R.-D., Fang, X., Wang, P., & Pan, H. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103260 · Cited by 107
Extracellular Vesicles in Liquid Biopsies: Potential for Disease Diagnosis
Liu, J., Chen, Y., Pei, F., Zeng, C., Yao, Y., Liao, W., & Zhao, Z. (2021) · BioMed Research International · doi:10.1155/2021/6611244 · Cited by 97
Why Target the Gut to Treat IgA Nephropathy?
Barratt, J., Rovin, B. H., Cattran, D., Floege, J., Lafayette, R., Tesar, V., Trimarchi, H., & Zhang, H. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.08.009 · Cited by 95
Self-citation
Metadata
- Authors
- Selvaskandan, H., Cheung, C. K., Muto, M., & Barratt, J.
- Affiliations
- University of Leicester (GB)
- Corresponding author
- Barratt, Jonathan
- Venue
- Clinical and Experimental Nephrology
- Published
- 2019-02-13
- Volume
- 23
- Issue
- 5
- Pages
- 577-588
- ISSN
- 1342-1751 (ISSN-L)
- 1437-7799
- PMC
- PMC6469670
- OpenAlex
- W2912114494
- Cited by
- 83
- References
- 109
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 16 · 2023: 14 · 2022: 24 · 2021: 14 · 2020: 9 · 2019: 1
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Clinical and Experimental Nephrology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion, cc-by)
- Funders
- National Institute for Health and Care Research (CL-2016-11-002, ACF-2015-11-005)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- IgA nephropathy, primary glomerulonephritis, renal replacement therapy, risk stratification, treatment response prediction, disease management strategies, diagnosis
- MeSH terms
- Animals, Glomerulonephritis, IGA, Humans, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.